Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

Supporting people with type 2 diabetes throughout the pandemic

This syndrome can develop in patients with COVID-19 if the virus enters the respiratory tract and damages the lungs

The Montreal Heart Institute (MHI) has announced that colchicine, a widely available low-cost drug, reduces acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and respiratory failure in pre-clinical models1. The article reporting these results was published yesterday by the Public Library of Science ONE (PLOS ONE) 1.